Navigation Links
Mary Hendrickson of GENCO Pharmaceutical Services Speaks Before Senate on the Topic of Drug Take-Back Programs
Date:7/8/2010

Important Issue at Crux of Environment, Drug Regulations, Child/Public Safety and Healthcare Reform

Pittsburgh, PA (Vocus) July 8, 2010 -- GENCO Supply Chain Solutions, North America’s second largest and a Global Top 50 third-party logistics provider, today announced that Mary Hendrickson, Director of Quality and Regulatory Affairs, GENCO Pharmaceutical Services, spoke on June 30 before the U.S. Senate Special Committee on Aging during a hearing on drug waste and disposal. Hendrickson’s testimony transcript and video of the hearing are available on the U.S. Senate Web site. Chairman Kohl (D-WI), along with Senators Corker (R-TN), Collins (R-ME) and Casey (D-PA), attended the hearing. The majority of the witnesses asked for changes to the Controlled Substance Act to allow non-DEA registrants the ability to accept controlled substances through take-back programs. The DEA is on record supporting H.R. 1359 which would give the DEA this authority.

Covered in the testimony is the intersection between drug regulations, environmental concerns and the human tragedy associated with overdoses on prescribed drugs found in medicine cabinets, a human health issue that could have implications within broader healthcare reform initiatives. The panel statements included a drug enforcement official who indicated that a nationwide drug take-back initiative is in the planning stages; a parent who lost a son due to the use of an unused prescription medication left in a medicine cabinet; and among others, Stevan Gressitt, Founding Director, Maine Institute for Safe Medicine, Faculty Associate University of Maine, Center on Aging, who discussed Maine’s statewide program allowing consumers to return unused drugs back to the DEA through the U.S. Postal Service – the program has recovered one ton of unused pharmaceuticals since 2007, saving the state $250,000 per year in associated costs.

Covered in Mary Hendrickson’s statement were the following:

 
  • The environmental and misuse/abuse concerns associated with improper disposal or non-disposal of medications, as often practiced by long term care facilities and in the home.
  • The simple yet highly regulated process of reverse distribution – to waste-to-energy facilities – of unsold medications from pharmacies, of which GENCO Pharmaceutical Services is the leading provider.
  • An overview of the GENCO take-back program in Wisconsin, which allowed for consumers to return unused medications for incineration in a waste-to-energy facility, meeting with great success from both public safety and environmental standpoints. During the six month program, 1,259 households returned 15,164 medications.
  • The process for handling pharmaceutical waste: Incineration of drugs provides an alternative to burning coal for electricity, resulting in a net greenhouse gas reduction, while keeping drugs out of landfills and the water supply. A 2002 U.S. Geological Survey study of 139 bodies of water across the country found that over 80 percent of the water samples were contaminated by prescription drugs, which have been shown to harm fish and wildlife.
  • The barrier to entry for GENCO into a consumer take-back market, despite the company’s standing as the leading provider of reverse distribution for the pharmaceutical industry’s overstocked and expired drugs. The Controlled Substance Act allows only for transfer of controlled substances among the DEA registrants. When a pharmacy dispenses the medication to a patient, the patient is not considered to be within the closed loop of distribution and is not a DEA registrant. As a result, reverse distributors as well as the other DEA registrants cannot take controlled substance product back from patients.

Other experts provided testimony presenting the opinion that the environmental, cost and safety benefits of take-back programs far outweigh the minimal risks of criminal diversion of controlled substances into a black market.

As the leader in pharmaceutical returns for industry, GENCO is well-poised to manage the logistics of a nationwide take-back program. Government’s healthcare reform initiatives may point the nation in the direction of improved data collection regarding the costs associated with over-prescribing, the human tragedy of overdoses associated with the medicine cabinet and the environmental issues with poor disposal – including the issue of medication seepage into the water supply. Legislation reform to address the legislation impeding drug take-back programs is expected over the next two years.

About GENCO Pharmaceutical Services
GENCO Pharmaceutical Services (GPS), a wholly owned subsidiary of GENCO Supply Chain Solutions, is the leader in pharmaceutical trade, sample and clinical trial returns and product recalls. GPS transforms pharmaceutical business activities into data-rich, systematic processes that provide critical business information and value to manufacturers, pharmacies and wholesalers. Through a state-of-the-art processing facility, the company provides comprehensive pharmaceutical returns management services to 67 pharmaceutical manufacturers, the biggest U.S. chain pharmacies, leading wholesalers and mail order pharmacies and specialty and infusion pharmacies. For more information, visit www.gencopharma.com.

About GENCO Supply Chain Solutions
GENCO Supply Chain Solutions is North America's 2nd largest and a Global Top 50 third-party logistics provider and the recognized leader in reverse logistics. The company manages 125 operations and 37 million square feet of warehouse space throughout North America for a diverse range of retail, manufacturing and government customers, including many Fortune 500 companies. The company provides initial and ongoing value through a complete range of solutions, including contract logistics, transportation logistics, parcel negotiation and audits, reverse logistics, damage research, product liquidation, pharmaceutical services, government solutions and supply chain technology solutions. For more information, visit www.genco.com.

###

Read the full story at http://www.prweb.com/releases/2010/07/prweb4237084.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved

Related medicine news :

1. SDI Reports: Novo Nordisk Takes Top Ranking Among Endocrinologists, According To Pharmaceutical Company Image Study
2. Chinese Biopharmaceutical Association Successfully Holds 15th Annual Conference
3. Omega Design Presented Pharmaceutical Packaging Solutions at the Healthcare Packaging Conference & Workshop 2010
4. HR Pharmaceuticals, Inc. to Launch and Showcase Flagship Product Line at the National Teaching Institute & Critical Care Nurses Exposition
5. Pharmaceutical companies provide EPA 100 drugs to help predict toxicity
6. HIRC Research Alert: New Study Identifies Best Pharmaceutical Company Account Managers and Program Offerings
7. SDI Reports: Pharmaceutical Promotion Spending Indicates Trend Toward Electronic and Online Promotion
8. Impact Systems Successfully Completes EMC Documentum Migration for Global Pharmaceutical Client
9. Sponsoring by the pharmaceutical industry can bias the results of drug studies
10. Jazz Pharmaceuticals to Present at the Barclays Capital 2010 Global Healthcare Conference
11. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. In ... benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued ... Sickle Cell Disease (SCD) is a disorder of the red blood cells, which can ...
(Date:6/24/2016)... ... ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida attorneys are recognized ... this recognition are considered among the top 2 percent of lawyers practicing within the ... this year’s Legal Elite Hall of Fame: Miami Shareholders Mark D. Bloom, Burt ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... , June 27, 2016 Jazz Pharmaceuticals ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of ... acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... p.m. (Eastern Daylight Time). As previously announced ... into a definitive merger agreement under which Jazz Pharmaceuticals ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... June 24, 2016 Dehaier Medical Systems Ltd. ... which develops, markets and sells medical devices and wearable ... signed a strategic cooperation agreement with Hongyuan Supply Chain ... Chain") on June 20, 2016, to develop Dehaier,s new ... cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s sales ...
Breaking Medicine Technology: